Lisata Therapeutics Stock Investor Sentiment

LSTA Stock  USD 2.77  0.01  0.36%   
About 54% of Lisata Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that many traders are impartial. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Lisata Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over two months ago at prnewswire.com         
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635
prnewswire News
over two months ago at insidermonkey.com         
Harmony Biosciences Holdings, Inc. Short Seller Sentiment is Bearish
insidermonkey News
over two months ago at businesswire.com         
Aditxts Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endo...
businesswire News
over two months ago at accesswire.com         
Stockholders Are Urged To Help The Schall Law Firm Investigate Spruce Biosciences, Inc. For Possible...
news
over two months ago at finance.yahoo.com         
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients...
Yahoo News
over two months ago at bizjournals.com         
Parse Biosciences scores victory in patent dispute
bizjournals News
over two months ago at insidermonkey.com         
Hedge Fund and Insider Trading News John Paulson, Steve Cohen, Ray Dalio, Warren Buffett, Dmitry Bal...
insidermonkey News
over two months ago at prnewswire.com         
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer R...
prnewswire News
over two months ago at thelincolnianonline.com         
Tyra Biosciences Shares Gap Up to 20.55
news
over two months ago at investing.com         
NEA 17 LP buys 8 million in MBX Biosciences shares
Investing News at Macroaxis
over two months ago at investing.com         
IGM Biosciences chief scientific officer sells 17k in stock
Investing News at Macroaxis
over two months ago at finance.yahoo.com         
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of ...
Yahoo News
over two months ago at businesswire.com         
Samenvatting Kaitie Kramer sluit zich aan bij Parse Biosciences als vicepresident Marketing
businesswire News
over two months ago at businesswire.com         
Riassunto Kaitie Kramer entra in Parse Biosciences come Vice Presidente del Marketing
businesswire News
over two months ago at thelincolnianonline.com         
Tyra Biosciences Trading 6 percent Higher
news
Far too much social signal, news, headlines, and media speculation about Lisata Therapeutics that are available to investors today. That information is available publicly through Lisata media outlets and privately through word of mouth or via Lisata internal channels. However, regardless of the origin, that massive amount of Lisata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lisata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lisata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lisata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lisata Therapeutics alpha.

Lisata Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Insider Buying CFO Alan Fuhrman Acquires 9,500 Shares of Tyra Biosciences Inc
11/01/2024
2
Wellington Management Group LLP Acquires New Stake in MBX Biosciences Inc
11/08/2024
3
Xenetic Biosciences Third Quarter 2024 Earnings Misses Expectations
11/15/2024
4
Artelo Biosciences Stock Surges Amid Strong Buy Ratings
11/20/2024
5
After Leaping 47 percent Shanghai OPM Biosciences Co., Ltd. Shares Are Not Flying Under The Radar
11/21/2024
6
Aptose Biosciences Inc. Announces Pricing of 8 Million Public Offering
11/22/2024
7
Forte Biosciences to Host RD Day December 3, 2024
11/25/2024
8
Marvel Biosciences Announces Promising New Data from Rett Syndrome Study and Plans to Discuss Orphan and Rare Disease Status with the FDA
11/26/2024

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
CEOs Directory
Screen CEOs from public companies around the world
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges